Patients in groups 2 and 3 received the recommended therapy for HF: 77-90% angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor antagonists (ARA), 77-90% beta-blockers, 55-61% mineralocorticoid receptor antagonists (MRA), and 100% diuretics. The gene discussed is NR3C2; the disease is hydrops fetalis.